Xiao-Fan Li, MD

Beijing, Beijing

Disclosures:

• Employment: none
• Compensation: none
• Ownership: none
• Leadership: none

Presentation(s):

• 3591 - Phase II Study of Induction Immunotherapy Combined with Platinum-Base Doublet Chemotherapy Followed by Immunotherapy and Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

  Monday, September 30, 2024
  8:00 AM – 9:00 AM ET